Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials-论文-万方医学网

首页> > Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials

Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials

导出原文传递

翻译打印收藏纠错

第一作者： Stephen V. Faraone

作者： Stephen V. Faraone ^[1] ; Roberto Gomeni ; Joseph T. Hull ; Gregory D. Busse ; Zare Melyan ; Welton O’Neal ; Jonathan Rubin ; Azmi Nasser

作者单位： Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical University ^[1]

关键词 Attention-deficit/hyperactivity disorder treatment response predictor ADHD-RS-5 CGI-I

发布时间 2022-09-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials

相似文献

同项目论文

相关期刊

检索历史 清除

Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials

相似文献

同项目论文

相关期刊

检索历史清除